June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
The United Kingdom Glaucoma Treatment Study (UKGTS): baseline characteristics and main outcomes
Author Affiliations & Notes
  • David Garway-Heath
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Gerassimos Lascaratos
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Catey Bunce
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • David Crabb
    Department of Optometry and Visual Science, City University, London, United Kingdom
  • Richard Russell
    Department of Optometry and Visual Science, City University, London, United Kingdom
  • Ameet Shah
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Katsuyoshi Suzuki
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Edward White
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Francesca Amalfitano
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships David Garway-Heath, Moorfields MDT (P), Carl Zeiss Meditec (F), Heidelberg Engineering (F), Reichert Technoloies (F), Ziemer Ophthalmic Systems AG (F), Pfizer Inc (F), Allergan (F), Allergan (C), Allergan (R), Alcon (C), Alcon (R), Bausch & Lomb (R), Merck (R), Santen (R), Quark (C), Teva (C), Topcon (F), OptoVue (F); Gerassimos Lascaratos, None; Catey Bunce, None; David Crabb, Allergan Inc. (R), Moorfields MDT (P); Richard Russell, None; Ameet Shah, None; Katsuyoshi Suzuki, None; Edward White, None; Francesca Amalfitano, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2619. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David Garway-Heath, Gerassimos Lascaratos, Catey Bunce, David Crabb, Richard Russell, Ameet Shah, Katsuyoshi Suzuki, Edward White, Francesca Amalfitano, ; The United Kingdom Glaucoma Treatment Study (UKGTS): baseline characteristics and main outcomes. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2619.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Medical IOP reduction is the standard initial treatment for open angle glaucoma (OAG), yet no randomized placebo-controlled study of medical IOP reduction has been undertaken previously.

 
Methods
 

The United Kingdom Glaucoma Treatment Study (UKGTS) is the first randomized, double-masked, placebo-controlled, multi-centre medical treatment trial for OAG. 516 newly-diagnosed (previously untreated) patients with OAG were prospectively recruited at 10 UK centres between 2007 and 2010.The observation period was 2 years, with subjects monitored by visual field (VF) testing, quantitative imaging, optic disc photography and tonometry at 11 visits. Eligible patients were assigned by concealed telephone allocation to treatment with latanoprost 0.005% or placebo. The primary outcome measure was time to VF deterioration within 24 months, based on Humphrey VF Analyzer GPA criteria.

 
Results
 

Mean (±SD) subject age was 66(±11) years and 52.9% were male. The baseline mean IOP (±SD) was 18.9±4mmHg in the better mean deviation (MD) eyes (median [IQR] MD -1.27dB [-2.37, -0.19]) and 19.9±4.6mmHg in the worse MD eyes (median [IQR] MD -3.30dB [-5.60, -1.98]). Survival analysis showed a significant difference in the time from baseline to confirmed VF progression between the two treatment groups (p=0.0012) (Fig.1). The adjusted hazard ratio by site was 0.498 (95% CI 0.332, 0.747). The median (IQR) MD slope for all eyes with reliable VFs on at least 5 visits was 0.17 (-0.34 to 0.51) dB/year and -0.05 (-0.70 to 0.49) dB/year for the latanoprost and placebo groups, respectively (p=0.0003). The mean IOP reduction from the pre-allocation visit to the first visit post-treatment allocation was greater in the latanoprost group (4.5mmHg) as compared to the placebo (0.6mmHg). 127 patients who did not reach an endpoint failed to complete 2 years’ follow-up 24.6%).

 
Conclusions
 

The UKGTS is the first randomized, placebo-controlled trial to show the efficacy of medical treatment in reducing VF deterioration in OAG. The observation period was short (2 years) compared to most trials; the analysis of deterioration velocity and inclusion of quantitative imaging has the potential to reduce the number of patients and/or duration required for subsequent clinical trials and will be modelled in subsequent analyses.

  
Keywords: 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×